Author: Taylor Warfield, Former Bain Manager and interviewer

Last Updated: September 2, 2026

 

ClearView exit opportunities are concentrated in life sciences: biotech and pharma corporate strategy, new product planning, business development and licensing, pricing and market access, medical affairs, life sciences investing, healthcare equity research, and top MBA programs. That focus is an advantage if you want a career in pharma or biotech and a constraint if you don't, so this article covers each path, what it pays, and how long you need to stay to reach it.

 

Before reading on:

 

Most candidates struggle to land interviews and even fewer turn them into offers. Watch my free training to learn how to triple your chances of landing interviews and increase your chances of receiving an offer by 8x.

 

👉 Watch for free

 

Key Takeaways

 

ClearView alumni exit almost entirely into life sciences roles, and the firm's own careers page ties the strongest outcomes to staying two or more years.

 

• Eight paths account for nearly every ClearView exit, and all but one sit inside pharma, biotech, medtech, or diagnostics

 

• ClearView states that alums with 2 or more years have moved on to top business schools and major life sciences companies

 

• Median total pay runs from $92,335 for Analysts to $226,308 for Engagement Managers, per Glassdoor data as of August 2026

 

• Common exit roles average $161,006 to $289,119 in total pay, based on 2026 Glassdoor figures

 

• The firm's dedicated Investor practice is the most direct route onto the buy side in life sciences

 

• Pivoting outside healthcare is the one genuinely hard move, and it usually requires an MBA in between

 

What Are ClearView Exit Opportunities?

 

ClearView exit opportunities are the roles consultants move into after leaving ClearView Healthcare Partners, a life sciences strategy firm founded in Boston in 2007. Nearly all of them sit inside the industry the firm serves: corporate and commercial strategy at pharma and biotech companies, business development, pricing and market access, medical affairs, life sciences investing, and top MBA programs.

 

ClearView is not a generalist firm and never has been. It advises biopharmaceutical, medical device, and diagnostics clients out of Boston, New York, San Francisco, London, and Gurgaon, and it sits among the top healthcare consulting firms by reputation.

 

That single-industry model is the whole story of the exit profile. You leave with two years of therapeutic area depth instead of two years of breadth across five industries.

 

Why Do ClearView Consultants Get Strong Life Sciences Exits?

 

ClearView consultants exit well into life sciences because their project work is already the work industry hiring managers need done. A pharma commercial lead evaluating a launch forecast is asking the same question a ClearView team answered last month for a different client.

 

There are four reasons the pipeline works so reliably.

 

The work maps directly onto industry job descriptions

 

ClearView's practice areas read like an org chart at a mid-size biotech: pharma and biotech strategy, medtech and diagnostics, pricing and market access, launch and commercialization, advanced analytics, and investor support. A hiring manager filling a new product planning role does not have to imagine how your experience transfers.

 

Single staffing produces unusually high project volume

 

ClearView's careers FAQ states that consultants are staffed on one project at a time and that typical project duration is 4 to 6 weeks. Do the arithmetic and a full year of work means roughly 9 to 11 distinct engagements, so two years puts about 20 different commercial problems on your resume.

 

That volume is the underrated part of the ClearView exit story. Most generalist consultants finish two years with 6 to 10 cases, not 20.

 

The training reputation carries weight with recruiters

 

ClearView placed 25th overall in the 2026 Vault Consulting 50 North America, ranking 5th for health sciences consulting and 8th for formal training. Life sciences recruiters read that formal training rank as a signal that you were taught to structure and present, not thrown at spreadsheets.

 

Ownership starts early and clients see your face

 

ClearView's own role descriptions say Analysts take ownership of part of the problem solving and are responsible for presenting findings to the client. Client-facing reps in year one are why ClearView Analysts interview well for industry roles that normally expect three years of experience.

 

What Are the Most Common ClearView Exit Opportunities?

 

Eight destinations account for nearly every ClearView exit. They are listed roughly in order of volume, from the most common to the most competitive.

 

1. Biotech and pharma corporate strategy

 

This is the single largest destination and the most natural one. Corporate strategy groups at pharma and biotech companies do portfolio prioritization, asset valuation, and long-range planning, which is close to what ClearView teams do for the same clients.

 

Titles range from Manager to Associate Director depending on your ClearView level. Consultants and Senior Consultants tend to land Manager or Senior Manager roles, while Engagement Managers compete for Associate Director.

 

2. New product planning and commercial strategy

 

New product planning teams shape the commercial case for an asset years before launch: target product profile, forecast, positioning, and launch sequencing. ClearView runs a dedicated launch and commercialization practice, so this exit is often a lateral step in scope with a title bump.

 

Brand and marketing roles sit next door and hire from the same pool. If you enjoyed the forecasting work more than the science, this is your path.

 

3. Business development and licensing

 

Business development and licensing groups run search and evaluate, in-licensing, and partnership deals, and they hire consultants specifically for opportunity assessment skills. Job postings in this space routinely name life sciences consulting as an accepted background alongside biotech business development and venture investing.

 

The catch is that these teams are top-heavy. Most openings are at Director level or above, so this is more often a second move than a first one.

 

4. Pricing and market access

 

Market access teams handle payer strategy, pricing, reimbursement, and health economics, and they are one of the fastest-growing functions in pharma. ClearView posts Pricing and Market Access consulting roles as a distinct track, which means you can build the specialization inside the firm before you exit into it.

 

GHO Capital, which took majority ownership of ClearView in a September 2021 recapitalization, has publicly named health economics, real-world evidence, and pricing and market access as growth adjacencies for the firm. Every year that plan runs, the market access exit gets easier for ClearViewers.

 

5. Medical affairs and MSL roles

 

Medical affairs is the exit that rewards the advanced degree you may already have. Medical Science Liaison roles pair scientific credibility with field-based relationship work, and Glassdoor puts average total pay at $210,744 in the United States based on 520 reported salaries in 2026.

 

This path is realistically open to ClearView Consultants and Senior Consultants with an MD or PhD. Analysts with a bachelor's degree rarely clear the credential bar.

 

6. Life sciences venture capital and private equity

 

Healthcare-focused funds hire consultants who can assess a scientific asset and a commercial market in the same conversation. Moving from consulting to private equity is competitive everywhere, and in life sciences the funds that hire ClearView alumni are the specialists rather than the generalist megafunds.

 

Here is the specific piece most guides miss. ClearView staffs a dedicated Investor practice and posts Investor-track roles such as Life Sciences Senior Consultant, Investor and Consulting Project Team Lead, Investor.

 

Getting onto that track means you spend your days doing commercial due diligence for the exact funds you want to join. If a buy-side exit is the goal, ask for Investor staffing in your first staffing conversation, not your third year.

 

7. Healthcare equity research and investment banking

 

Biotech equity research desks value people who can read a clinical trial readout and build a revenue model from it. This exit is more common for ClearViewers with a PhD in a therapeutic area an analyst covers, since the science is the differentiator and the modeling can be taught.

 

Healthcare investment banking is the harder version of the same move. Banks recruit heavily from their own analyst classes, so expect to enter at a level below your ClearView tenure.

 

8. MBA programs and lateral moves to larger firms

 

ClearView states on its careers site that alums with two or more years have moved on to prestigious business schools and to roles at key life sciences companies. A science degree plus quantified commercial work is a genuinely differentiated MBA profile next to a pool full of bankers.

 

The lateral move to a larger firm is the other option here. Experienced hire recruiting at McKinsey, BCG, and Bain almost always routes through the healthcare practice, and you still have to pass full case interviews to get in.

 

Candidates underestimate this every year. If you want to learn case interviews quickly, my case interview course walks you through proven strategies in as little as 7 days.

 

What Do ClearView Exit Opportunities Pay?

 

Most ClearView exits into industry come with a title bump and flat or slightly higher cash, plus better hours. The big compensation jumps happen on the buy side and at Director level in industry, not on the first move out.

 

Start with what you would be giving up. These are Glassdoor's reported median total pay figures for ClearView as of August 2026.

 

ClearView level	Median total pay	Typical background
Analyst	$92,335	Bachelor's or master's in the life sciences
Senior Analyst	$103,518	Over 1.5 years of life sciences consulting
Consultant	$135,994	MD or PhD, or a promoted Senior Analyst
Senior Consultant	$163,850	Advanced degree plus 2 or more years in the field
Engagement Manager	$226,308	Promoted Senior Consultant leading full projects

 

Source: Glassdoor reported median total pay for ClearView Healthcare Partners, August 2026. ClearView's own posted ranges on its job listings run $110,000 to $120,000 for a Senior Analyst and $190,000 to $220,000 for Consulting Project Team Lead roles.

 

Now the destinations. These are national Glassdoor averages for the exit roles themselves in 2026, not ClearView-specific figures.

 

Exit role	Average total pay	Who usually competes for it
Pharma business development manager	$161,006	Senior Analysts and Consultants
Medical Science Liaison	$210,744	Consultants with an MD or PhD
Corporate strategy	$221,148	Senior Consultants and Engagement Managers
Associate Director, Strategy	$265,820	Engagement Managers
Director, Corporate Development	$289,119	Associate Principals and above

 

Source: Glassdoor national average total pay by job title, 2026. The Associate Director figure draws on 229 reported salaries and the Corporate Development figure on 223.

 

Read those two tables together and the pattern is clear. An Engagement Manager at $226,308 who exits to an Associate Director strategy role at roughly $265,820 gains money and hours, while an Analyst at $92,335 who exits early trades a fast promotion track for a modest raise.

 

How Long Should You Stay at ClearView Before Exiting?

 

Stay at least two years. ClearView says it directly on its careers site: alums with two or more years have moved on to prestigious business schools and impactful roles at key life sciences companies.

 

That is a rare thing for a firm to publish, and it lines up with what I see in practice. The two-year mark is where you stop being an executor and start being someone who has owned a workstream end to end.

 

The title you carry when you leave matters more at ClearView than at most firms, because the ladder has seven rungs below partner.

 

1. Analyst: owns part of the problem solving and presents findings to the client
   
   
2. Senior Analyst: owns a full workstream and may oversee an Analyst
   
   
3. Consultant: develops methodology and drives to strategic implications
   
   
4. Senior Consultant: acts as project lead and mentors junior team members
   
   
5. Engagement Manager: leads multiple projects and owns the client relationship day to day
   
   
6. Associate Principal: drives client relationships and gets exposure to business development
   
   
7. Principal or Managing Director: full client ownership from business development through delivery

 

Here is the practical problem that costs ClearViewers offers. Industry recruiters read "Consultant" as an MBA-level title, but at ClearView it is often the entry title for a PhD, so a recruiter can undervalue you by a full level.

 

Fix it on the page rather than in the interview. Lead your consulting resume for experienced hires with scope and team size, and put the title second.

 

If you want that document reviewed by someone who has read thousands of them, my resume review and editing service comes with unlimited revisions and a 24-hour turnaround.

 

How Do ClearView Exit Opportunities Compare to MBB?

 

ClearView exits are narrower than MBB exits, not weaker. Inside pharma and biotech, a ClearView alum often beats an MBB generalist for the same role because the therapeutic knowledge is already there.

 

Outside healthcare the comparison flips hard. MBB exit opportunities travel into tech, private equity, consumer goods, and general management, and a life sciences boutique brand simply does not open those doors the same way.

 

Factor	ClearView	MBB
Industry range	Pharma, biotech, medtech, diagnostics only	Any industry, including healthcare
Year one depth	High, since every project is life sciences	Moderate, unless you join the health practice
Brand outside healthcare	Limited recognition	Recognized in every industry
Buy-side access	Healthcare-focused VC and PE funds	Generalist PE, hedge funds, and healthcare funds
Non-healthcare pivot	Difficult without an MBA in between	Straightforward at any point
Project volume in 2 years	Roughly 20, given 4 to 6 week projects	Roughly 6 to 10 on longer cases

 

The honest read: pick ClearView if you already know you want life sciences, and pick a generalist firm if you want to keep optionality open. This is the same tradeoff that runs through every healthcare consulting career path decision between specialists and generalists.

 

What Are the Limits of ClearView Exit Opportunities?

 

Three constraints show up again and again, and no article that only lists the upside is being straight with you.

 

The non-healthcare pivot is genuinely hard

 

Two years of oncology forecasting reads as specialist experience to a tech or consumer recruiter. The reliable bridge is an MBA, which resets your industry label and gives you a recruiting cycle to change lanes.

 

Generalist private equity stays mostly closed

 

Generalist funds screen for LBO modeling and deal execution reps that ClearView projects do not build. Healthcare-focused funds are the realistic target, and the Investor practice is how you get in front of them.

 

Work-life balance is a real reason people leave early

 

Glassdoor reviewers rate ClearView 3.4 out of 5 on career opportunities as of August 2026 across 278 reviews, and that rating has slipped 4% over the prior twelve months. Hours are a recurring theme in the reviews, and leaving before two years is the most common way people cut short their own exit options.

 

How Do You Set Yourself Up for the Best Exit?

 

The best exits are engineered from your first staffing conversation, not your last performance review. Here are the six moves that matter most.

 

Tip #1: Pick a therapeutic area and go deep

 

Industry hiring managers hire for oncology, immunology, rare disease, or neuro, not for "life sciences." Three projects in one therapeutic area beat nine scattered across nine.

 

Tip #2: Ask for the exit function before you need it

 

ClearView runs distinct tracks for pricing and market access, launch and commercialization, corporate strategy, new product planning, and investor support. Whichever exit you want, get staffed on the matching track a year ahead of your search.

 

Tip #3: Keep a running project log

 

With projects turning over every 4 to 6 weeks, details evaporate fast. Write down the client type, the question, your workstream, and the quantified outcome the week each project ends.

 

Tip #4: Build relationships with client-side counterparts

 

Your client contacts are the people who will hire you or refer you, and you meet 20 sets of them in two years. Staying in touch after a project closes does more for your exit than any amount of cold networking later.

 

Tip #5: Translate your title on paper

 

Write "Consultant (project lead, teams of 4 to 6)" rather than "Consultant." Recruiters outside consulting do not know ClearView's ladder and will not go looking for the context.

 

Tip #6: Keep your case skills warm if MBB is on the list

 

A lateral move to a larger firm still runs through full case rounds, and the format is not the same as a ClearView case interview. Give yourself three months of structured practice rather than assuming the day job covers it.

 

ClearView exit opportunities reward patience more than almost any other consulting exit path, because the firm's own two-year threshold is the line between a junior industry role and a real strategy seat. Decide now which of the eight paths you want, then get staffed on the track that feeds it.

 

Frequently Asked Questions

 

What are the most common ClearView exit opportunities?

 

The most common exits are corporate and commercial strategy roles at pharma and biotech companies, new product planning, business development and licensing, pricing and market access, medical affairs, life sciences investing, healthcare equity research, and top MBA programs. Corporate and commercial strategy is the single largest destination because the work maps almost one to one onto ClearView project work. Nearly every path sits inside pharma, biotech, medtech, or diagnostics.

 

How long do people stay at ClearView before leaving?

 

Two to four years is the normal range. ClearView states on its careers page that alums with two or more years at the firm have moved on to prestigious business schools and roles at key life sciences companies. Leaving before the two-year mark usually means exiting as an Analyst, which limits you to more junior industry roles.

 

Can you go to MBB after ClearView?

 

Yes, but it is one of the harder moves and it usually happens through the healthcare or life sciences practice rather than the generalist pool. Experienced hire processes at McKinsey, BCG, and Bain still require you to pass full case interviews, so your ClearView track record does not exempt you from the same bar. Most people who make the jump do it within their first three years, before their profile is read as a life sciences specialist.

 

Do ClearView alumni get into top MBA programs?

 

Yes. ClearView highlights on its careers page that alums with two or more years have gone on to prestigious business schools. A science undergraduate degree plus quantified commercial strategy work is a distinctive profile in an applicant pool crowded with banking and generalist consulting candidates.

 

Are ClearView exit opportunities worse than MBB exit opportunities?

 

They are narrower, not worse. Inside pharma, biotech, and life sciences investing, ClearView alumni compete well because they arrive with therapeutic area knowledge that generalist consultants have to build. Outside healthcare, the brand carries much less weight, and pivoting to tech, consumer, or industrials is genuinely hard without an MBA in between.

 

Can you exit ClearView into private equity or venture capital?

 

Yes, into healthcare-focused funds rather than generalist ones. ClearView runs a dedicated Investor practice and posts Investor-track consulting roles, and that commercial due diligence work is the most direct on-ramp to the buy side. Generalist private equity remains difficult because those funds recruit for LBO modeling skills that ClearView projects do not build.

 

Everything You Need to Land a Consulting Offer

 

Need help passing your interviews?

• Case Interview Course: Become a top 10% case interview candidate in 7 days while saving yourself 100+ hours
  
  
• Fit Interview Course: Master 98% of consulting fit interview questions in a few hours
  
  
• Interview Coaching: Accelerate your prep with 1-on-1 coaching with Taylor Warfield, former Bain interviewer and best-selling author

 

Need help landing interviews?

• Resume Review & Editing: Craft the perfect resume with unlimited revisions and 24-hour turnaround

 

Need help with everything?

• Consulting Offer Program: Go from zero to offer-ready with a complete system

 

Not sure where to start?

• Free 40-Minute Training: Triple your chances of landing consulting interviews and 8x your chances of passing them